Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
JERSEY CITY, NJ—Brady Patrick Priest, CEO of Home Care at Clover Health Investments, Corp. (NASDAQ:CLOV), recently sold 75,000 shares of the company’s Class A common stock. The transactions took place on March 6, 2025, at an average price of $3.68 per share, amounting to a total value of $276,000. The stock, which has shown significant volatility with a 355% return over the past year, currently trades near analyst targets ranging from $4 to $6 per share.
Following these sales, Priest retains ownership of 2,418,151 shares in the company. The sales were executed in multiple transactions with prices ranging from $3.68 to $3.70 per share. The transactions were disclosed in a Form 4 filing with the Securities and Exchange Commission. According to InvestingPro, the stock currently trades near its Fair Value, with 7 additional exclusive insights available to subscribers.
In other recent news, Clover Health reported its fourth-quarter 2024 earnings, exceeding analysts’ expectations with an earnings per share (EPS) of -$0.04, compared to the forecasted -$0.07. However, the company’s revenue fell short of projections, reaching $330.7 million against the expected $348.04 million. Despite the revenue miss, Clover Health demonstrated significant growth in insurance revenue and achieved an adjusted EBITDA profitability exceeding $70 million for 2024. The company also reported a 9% increase in full-year insurance revenue, totaling $1.345 billion. In a related development, Canaccord Genuity raised its price target for Clover Health to $4.50, maintaining a Buy rating on the stock. The firm cited the company’s strategic focus on expanding its Medicare Advantage market share, particularly in Georgia and New Jersey. Canaccord highlighted Clover Health’s transition to positive adjusted EBITDA as a factor in their revised price target. These developments indicate a positive outlook from analysts regarding Clover Health’s growth strategy and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.